Skip to main content

David Ramos Vicente

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

David Ramos Vicente

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Camille Guillard Sirieix, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

Pendent

IP: Jordi Bove Badell
Collaborators: David Ramos Vicente, Miriam Izquierdo Sans, Laia Perez Lasarte
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 64800
Reference: FJC2021-047862-I
Duration: 01/01/2023 - 31/12/2024

Ministerio de Ciencia

Characterization of the CD8 T cell response in Parkinson’s disease for the development of preventive and therapeutic strategies that halt the progression of the disease: SARS-Cov-2-induced long term-hyposmia as a possible prodromal stage

IP: Jordi Bove Badell
Collaborators: Miquel Vila Bover, Alejandro Ferré Masó, Oriol de Fabregues-Boixar Nebot, Carles Lorenzo Bosquet, Thais Cuadros Arasa, Antonio Palasi Franco, David Ramos Vicente
Funding agency: Instituto de Salud Carlos III
Funding: 165770
Reference: PI21/01358
Duration: 01/01/2022 - 30/06/2026

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Santiago Martin Grieve

Santiago Martin Grieve

Research technician
Cardiovascular Diseases
Read more
Jordi Martínez Quintanilla

Jordi Martínez Quintanilla

Postdoctoral researcher
Read more
Luciana Midaglia Fernandez

Luciana Midaglia Fernandez

Research technician
Clinical Neuroimmunology
Read more
Mar Costa Roger

Mar Costa Roger

Postdoctoral researcher
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.